Podcast on the Management of Adverse Events Associated with Lorlatinib

[Chinese Expert Consensus on Management of Special Adverse Effects Associated with Lorlatinib]

Anaplastic lymphoma kinase (ALK) fusions represent the second most common oncogenic driver mutation in non-small cell lung cancer (NSCLC). As the new class of 3rd generation of ALK tyrosine kinase inhibitor (TKI), lorlatinib has shown robust potency and brain-penetrant clinical activity against a wide spectrum of multiple resistance mutations within the ALK domain detected during crizotinib and 2nd generation ALK TKI treatment. Lorlatinib is generally well-tolerated with unique adverse drug reaction/adverse event, including hyperlipidemia and central nervous system effects, which are mostly mild to moderate severity and manageable through dosage modifications and/or standard medical intervention. For advanced NSCLC with ALK positivity, patients should be evaluated for baseline characteristics and pre-existing medication, informed of the potential toxicities, and periodically monitored to balance benefits and risks. Moreover, a multidisciplinary group of experts is essential to establish a comprehensive diagnostic and therapeutic strategy.
.

A case study of using cross-linked hyaluronic acid for upper eyelid rejuvenation

Introduction: The aim of study is to rejuvenate upper eyelid by injecting cross-linked hyaluronic acid into it and correct the appearance of the eye whether it is sunken or hollowed. Method: thirty participants divided into 2 groups. Group A: a patient with sunken eye, Group B: a patient with hollowed eye and mild excess skin and. A cross-linked hyaluronic acid 20mg/ml (Hyamira/Italian brand) was injected into upper eyelid via 25gauge blunt cannula. Assessment was done by taking photos and measurements. Follow up was made on basis of 2 weeks and 3 months. Result: cross sectional study of 30 patients have left and right side upper eyelid rejuvenation, mean age of patients is (37.5 ± 8.2) years old, 19 (63.3%) patients have hallowed mild abnormality and 11 (36.67%) of them have sunken eye abnormality. There is significant difference between the mean of period of injection according to group (A&B). group A more have injection time than group A in period 2 weeks and 3 months. Conclusion: obvious upper eyelid rejuvenation, youthful appearance with no more sunken or hollowed eye with more than 1 year.